Terminal deoxynucleotidyl transferase (TdT)-containing peripheral blood mononuclear cells during remission of acute lymphoblastic leukemia: Low sensitivity and specificity prevent accurate prediction of relapse

Purine nucleoside phosphorylase (PNP) activity has been measured in the lymphoblasts of 22 patients with acute lymphoblastic leukemia (ALL) and correlated with routine immunologic cell surface markers. Fourteen of the 22 patients were considered to have non-T, non-B-cell ALL; 8 patients had T-cell disease. The median PNP activity in 21 control samples of normal peripheral blood mononuclear cells was 83 U. The median PNP activity of the non-T, non-B lymphoblasts was 79 U. No statistical difference in PNP activity between these two groups could be discerned (p < 0.37). In contrast, T-cell lymphoblasts demonstrated diminished PNP activity with a median of 38 U. The differences in activity between T lymphoblasts and both non-T, non-B leukemic cells and normal peripheral blood mononuclear cells were significant (p < 0.001 and p < 0.003, respectively). Evaluation of PNP activity provides further evidence of biochemical heterogeneity among immunologic subclasses of ALL.

Download Full-text

Low constitutive activity of aryl hydrocarbon hydroxylase in phytohaemoagglutinin-stimulated peripheral blood mononuclear cells of children after treatment for acute lymphoblastic leukemia

Cancer Letters ◽

10.1016/0304-3835(82)90114-8 ◽

1982 ◽

Vol 17 (1) ◽

pp. 95-99

Author(s):

A.L. Pawlak ◽

K. Wiktorowicz ◽

B. Duczmal-Szewczuk

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Lymphoblastic Leukemia ◽

Constitutive Activity ◽

Aryl Hydrocarbon Hydroxylase ◽

Peripheral Blood Mononuclear ◽

Aryl Hydrocarbon ◽

Blood Mononuclear Cells

Download Full-text

Purine nucleoside phosphorylase activity in acute lymphoblastic leukemia

Blood ◽

10.1182/blood.v56.3.380.380 ◽

1980 ◽

Vol 56 (3) ◽

pp. 380-382 ◽

Cited By ~ 27

Author(s):

J Blatt ◽

GH Reaman ◽

N Levin ◽

DG Poplack

Keyword(s):

Acute Lymphoblastic Leukemia ◽

T Cell ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Purine Nucleoside Phosphorylase ◽

Mononuclear Cells ◽

Lymphoblastic Leukemia ◽

Peripheral Blood Mononuclear ◽

Normal Peripheral Blood ◽

Blood Mononuclear Cells

Abstract Purine nucleoside phosphorylase (PNP) activity has been measured in the lymphoblasts of 22 patients with acute lymphoblastic leukemia (ALL) and correlated with routine immunologic cell surface markers. Fourteen of the 22 patients were considered to have non-T, non-B-cell ALL; 8 patients had T-cell disease. The median PNP activity in 21 control samples of normal peripheral blood mononuclear cells was 83 U. The median PNP activity of the non-T, non-B lymphoblasts was 79 U. No statistical difference in PNP activity between these two groups could be discerned (p < 0.37). In contrast, T-cell lymphoblasts demonstrated diminished PNP activity with a median of 38 U. The differences in activity between T lymphoblasts and both non-T, non-B leukemic cells and normal peripheral blood mononuclear cells were significant (p < 0.001 and p < 0.003, respectively). Evaluation of PNP activity provides further evidence of biochemical heterogeneity among immunologic subclasses of ALL.

Download Full-text

Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody

Blood ◽

10.1182/blood.v77.5.1044.1044 ◽

1991 ◽

Vol 77 (5) ◽

pp. 1044-1049 ◽

Cited By ~ 7

Author(s):

K Oshimi ◽

T Seto ◽

Y Oshimi ◽

M Masuda ◽

K Okumura ◽

...

Keyword(s):

T Cells ◽

Acute Lymphoblastic Leukemia ◽

Cytotoxic T Lymphocytes ◽

Peripheral Blood Mononuclear Cells ◽

Mononuclear Cells ◽

Lymphoblastic Leukemia ◽

Interleukin 2 ◽

Leukemic Cells ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells

Abstract An anti-CD3 Fab' x anti-CD10 Fab' bispecific hybrid F(ab')2 antibody (Ab) was generated. This bispecific Ab had a molecular mass of 100 to 110 Kd, and the capacity to react with both CD3+ T cells and CD10+ acute lymphoblastic leukemia (ALL) cells. We studied whether cytotoxic T lymphocytes (CTLs) could lyse patient CD10+ ALL cells after addition of the bispecific Ab. As effector CTLs, interleukin-2 (IL-2)-stimulated peripheral blood mononuclear cells (PBMCs) and CTL clones were used. When IL-2-stimulated PBMCs were assayed for cytotoxicity to 61Cr- labeled CD10+ ALL cells, their activity was shown to be markedly enhanced by the addition of the bispecific Ab. Most of the CTL clones established lacked cytotoxicity for CD10+ ALL cells, but addition of the bispecific Ab induced a significant level of cytotoxicity. CTLs derived from ALL patients also showed significant cytotoxicity for autologous CD10+ ALL cells after addition of the bispecific Ab. However, this Ab did not affect the cytotoxicity of CTLs when CD10- leukemic cells were used as the targets. These findings suggest that the bispecific Ab can be used for immunotherapy in patients with CD10+ ALL.

Download Full-text

Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody

Blood ◽

10.1182/blood.v77.5.1044.bloodjournal7751044 ◽

1991 ◽

Vol 77 (5) ◽

pp. 1044-1049

Author(s):

K Oshimi ◽

T Seto ◽

Y Oshimi ◽

M Masuda ◽

K Okumura ◽

...

Keyword(s):

T Cells ◽

Acute Lymphoblastic Leukemia ◽

Cytotoxic T Lymphocytes ◽

Peripheral Blood Mononuclear Cells ◽

Mononuclear Cells ◽

Lymphoblastic Leukemia ◽

Interleukin 2 ◽

Leukemic Cells ◽

Peripheral Blood Mononuclear ◽

Blood Mononuclear Cells

An anti-CD3 Fab' x anti-CD10 Fab' bispecific hybrid F(ab')2 antibody (Ab) was generated. This bispecific Ab had a molecular mass of 100 to 110 Kd, and the capacity to react with both CD3+ T cells and CD10+ acute lymphoblastic leukemia (ALL) cells. We studied whether cytotoxic T lymphocytes (CTLs) could lyse patient CD10+ ALL cells after addition of the bispecific Ab. As effector CTLs, interleukin-2 (IL-2)-stimulated peripheral blood mononuclear cells (PBMCs) and CTL clones were used. When IL-2-stimulated PBMCs were assayed for cytotoxicity to 61Cr- labeled CD10+ ALL cells, their activity was shown to be markedly enhanced by the addition of the bispecific Ab. Most of the CTL clones established lacked cytotoxicity for CD10+ ALL cells, but addition of the bispecific Ab induced a significant level of cytotoxicity. CTLs derived from ALL patients also showed significant cytotoxicity for autologous CD10+ ALL cells after addition of the bispecific Ab. However, this Ab did not affect the cytotoxicity of CTLs when CD10- leukemic cells were used as the targets. These findings suggest that the bispecific Ab can be used for immunotherapy in patients with CD10+ ALL.

Download Full-text